This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Henry Schein (HSIC) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
The timing of Good Friday is likely to dampen sales at Henry Schein (HSIC) in second-quarter 2017. Meanwhile, geographic expansion should continue.
Can Illumina (ILMN) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Illumina (ILMN) is well poised to witness steady top-line growth in Q2. Yet, the bottom line may remain stressed.
Will Stryker (SYK) Deliver a Beat this Earnings Season?
by Zacks Equity Research
The growing adoption of Stryker's (SYK) MAKO robots is expected to drive second-quarter 2017 sales in the orthopedic and reconstructive surgery market.
Is a Surprise in Store for ResMed (RMD) in Q4 Earnings?
by Zacks Equity Research
Currency headwind is likely to dampen ResMed's (RMD) gains in the COPD and sleep apnea market.
McKesson (MCK) Q1 Earnings: Stock Likely to Beat Estimates?
by Zacks Equity Research
McKesson's (MCK) strategic acquisitions and promising guidance raise optimism for the first quarter of fiscal 2018.
IDEXX Laboratories (IDXX) Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) Companion Animal Group business might drive its performance in Q2.
What's in Store for Express Scripts (ESRX) in Q2 Earnings?
by Zacks Equity Research
Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Express Scripts' (ESRX) growth in the second quarter.
Baxter International (BAX) Q2 Earnings: What's in Store?
by Zacks Equity Research
Despite an upbeat guidance, lower cyclophosphamide sales are likely to mar Baxter International (BAX) performance in the second quarter 2017.
Varian Medical (VAR) Q3 Earnings: Is a Surprise in Store?
by Zacks Equity Research
Varian Medical Systems' (VAR) oncology business strength might drive its performance in Q3.
Align Technology (ALGN) Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
Align Technology (ALGN) might ride high in Q2 banking on growth in the Invisalign space.
Is a Surprise in Store for CR Bard (BCR) in Q2 Earnings?
by Zacks Equity Research
Growing adoption of the company's flagship Lutonix drug coated-balloon is expected to benefit C.R. Bard's (BCR) performance in the second quarter.
GNC Holdings (GNC) Q2 Earnings: Disappointment in the Cards?
by Zacks Equity Research
We do not expect GNC Holdings (GNC) to beat estimates in Q2 earnings on account of a tough competitive landscape and currency headwinds.
Edwards Lifesciences (EW) Q2 Earnings: A Surprise in Store?
by Zacks Equity Research
Edwards Lifesciences (EW) will likely ride high in Q2 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve space.
Can Quest Diagnostics (DGX) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
Weak revenue per requisition performance and reimbursement pressure might dampen Quest Diagnostics' (DGX) benefits from esoteric testing business, infectious disease testing and prescription drug monitoring business growth.
Align Technology Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Share price of San Jose, CA-based Align Technology, Inc. (ALGN) reached a new 52-week high of $157.86 on Jul 17, eventually closing a bit lower at $156.21.
Stryker Poised on Solid Product Portfolio and Acquisitions
by Zacks Equity Research
On Jul 17, we issued an updated research report on Kalamazoo, MI-based Stryker Corporation (SYK), one of the largest medical device companies in the global orthopedic market.
5 Stocks with Impressive Sales Growth Worth Investing In
by Zacks Equity Research
Sales are often more closely monitored than earnings when assessing the growth of a business.
Company News for June 20, 2017
by Zacks Equity Research
Companies in the News are: RICE,EQT,RIGL,NVDQ,SYK,VRX
Novadaq Technologies (NVDQ) Stock Soars 95% on Stryker Acquisition Deal
by Megan Sanks
On Monday, NOVADAQ Technologies Inc. (NVDQ) announced that Stryker Corporation (SYK) has agreed to acquire the company for $11.75 per share in cash, putting NOVADAQ's total worth at $701 million.
Stryker (SYK) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Stryker Corporation (SYK), headquartered in Kalamazoo, MI, scaled a new 52-week high of $141.21 on May 25, eventually closing a little lower at $140.85.
The Zacks Analyst Blog Highlights: Kraft Heinz, Nike, Stryker, DISH Network, TD Ameritrade and Freeport-McMoRan
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Kraft Heinz, Nike, Stryker, DISH Network, TD Ameritrade and Freeport-McMoRan
Top Research Reports for Today: KHC, NKE, SYK & More
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Kraft Heinz (KHC), Nike (NKE) and Stryker (SYK).
Should You Sell Stryker (SYK) Stock Before Earnings?
by Zacks Equity Research
Stryker (SYK) might report a beat in the to be reported quarter on the back of its favorable Zacks Rank and positive Earnings ESP.
Medical Product Stocks Earnings on Apr 25: SYK, EW, LH
by Zacks Equity Research
Medical is one of the broader sectors among the 16 Zacks sectors that are expected to report earnings growth in the first quarter.
Will Stryker (SYK) Deliver a Beat this Earnings Season?
by Zacks Equity Research
Stryker Corporation (SYK), a leading player in the medical technology space, is set to report first-quarter 2017 results on Apr 25 after the bell.